Skip to main content
. Author manuscript; available in PMC: 2010 Jan 1.
Published in final edited form as: Semin Radiat Oncol. 2009 Jan;19(1):53–62. doi: 10.1016/j.semradonc.2008.09.010

Figure 1.

Figure 1

Study schema for a multi-institutional study evaluating the feasibility and efficacy of combining lapatinib, a dual EGFR and Her-2 tyrosine kinase inhibitor, with radiation therapy in patients who cannot tolerate chemoradiation treatment for locally advanced HNSCC